These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
824 related articles for article (PubMed ID: 25884814)
41. S-1 and irinotecan plus bevacizumab as second-line chemotherapy for patients with oxaliplatin-refractory metastatic colorectal cancer: a multicenter phase II study in Japan (KSCC1102). Miyamoto Y; Tsuji A; Tanioka H; Maekawa S; Kawanaka H; Kitazono M; Oki E; Emi Y; Murakami H; Ogata Y; Saeki H; Shimokawa M; Natsugoe S; Akagi Y; Baba H; Maehara Y Int J Clin Oncol; 2016 Aug; 21(4):705-712. PubMed ID: 26746689 [TBL] [Abstract][Full Text] [Related]
42. [KRAS mutation does not influence oxaliplatin or irinotecan efficacy, in association with bevacizumab, in first line treatment of metastatic colorectal cancer]. Cabart M; Frénel JS; Campion L; Ramée JF; Dupuis O; Senellart H; Hiret S; Douillard JY; Bennouna J Bull Cancer; 2016 Jun; 103(6):541-51. PubMed ID: 27155924 [TBL] [Abstract][Full Text] [Related]
43. A randomized phase II trial of pemetrexed plus irinotecan (ALIRI) versus leucovorin-modulated 5-FU plus irinotecan (FOLFIRI) in first-line treatment of locally advanced or metastatic colorectal cancer. Underhill C; Goldstein D; Gorbounova VA; Biakhov MY; Bazin IS; Granov DA; Hossain AM; Blatter J; Kaiser C; Ma D Oncology; 2007; 73(1-2):9-20. PubMed ID: 18334829 [TBL] [Abstract][Full Text] [Related]
44. Retrospective analysis of the international standard-dose FOLFIRI (plus bevacizumab) regimen in Japanese patients with unresectable advanced or recurrent colorectal carcinoma. Nishi T; Hamamoto Y; Warita E; Miyamoto J; Akutsu N; Yamanaka Y; Nagase M; Fujii H Int J Clin Oncol; 2011 Oct; 16(5):488-93. PubMed ID: 21416239 [TBL] [Abstract][Full Text] [Related]
45. A randomized, placebo-controlled phase ii study evaluating the reduction of neutropenia and febrile neutropenia in patients with colorectal cancer receiving pegfilgrastim with every-2-week chemotherapy. Hecht JR; Pillai M; Gollard R; Heim W; Swan F; Patel R; Dreiling L; Mo M; Malik I Clin Colorectal Cancer; 2010 Apr; 9(2):95-101. PubMed ID: 20378503 [TBL] [Abstract][Full Text] [Related]
46. Phase I study of combination therapy with irinotecan, leucovorin, and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for advanced colorectal cancer in Japanese patients. Sasaki Y; Hamaguchi T; Arai T; Goto A; Ura T; Muro K; Yamada Y; Shirao K; Shimada Y Anticancer Res; 2014 Apr; 34(4):2029-34. PubMed ID: 24692743 [TBL] [Abstract][Full Text] [Related]
47. Observational Cohort Study of Patients With Metastatic Colorectal Cancer Initiating Chemotherapy in Combination With Bevacizumab (CONCERT). Bennouna J; Phelip JM; André T; Asselain B; Sébastien Koné ; Ducreux M Clin Colorectal Cancer; 2017 Jun; 16(2):129-140.e4. PubMed ID: 28277294 [TBL] [Abstract][Full Text] [Related]
48. First-line therapy for metastatic colorectal carcinoma: modified FOLFOX4 or FOLFIRI-bevacizumab. Odabas H; Ozdemir N; Abali H; Oksuzoglu B; Isik M; Uncu D; Cihan S; Seker M; Zengin N J BUON; 2011; 16(2):247-52. PubMed ID: 21766493 [TBL] [Abstract][Full Text] [Related]
49. Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: prespecified subgroup analyses from the VELOUR trial. Tabernero J; Van Cutsem E; Lakomý R; Prausová J; Ruff P; van Hazel GA; Moiseyenko VM; Ferry DR; McKendrick JJ; Soussan-Lazard K; Chevalier S; Allegra CJ Eur J Cancer; 2014 Jan; 50(2):320-31. PubMed ID: 24140268 [TBL] [Abstract][Full Text] [Related]
50. Regimen selection for first-line FOLFIRI and FOLFOX based on UGT1A1 genotype and physical background is feasible in Japanese patients with advanced colorectal cancer. Ishida H; Fujita K; Akiyama Y; Sunakawa Y; Yamashita K; Mizuno K; Miwa K; Kawara K; Ichikawa W; Ando Y; Saji S; Sasaki Y Jpn J Clin Oncol; 2011 May; 41(5):617-23. PubMed ID: 21310730 [TBL] [Abstract][Full Text] [Related]
51. Phase II study of bevacizumab, capecitabine, and oxaliplatin followed by bevacizumab plus erlotinib as first-line therapy in metastatic colorectal cancer. Muñoz A; Pericay C; García-Girón C; Alonso V; Dueñas R; Cirera L; Rivera F; Falcó E; Bustos IA; Salud A Oncol Res; 2013; 21(4):181-91. PubMed ID: 24762224 [TBL] [Abstract][Full Text] [Related]
52. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial. Rödel C; Graeven U; Fietkau R; Hohenberger W; Hothorn T; Arnold D; Hofheinz RD; Ghadimi M; Wolff HA; Lang-Welzenbach M; Raab HR; Wittekind C; Ströbel P; Staib L; Wilhelm M; Grabenbauer GG; Hoffmanns H; Lindemann F; Schlenska-Lange A; Folprecht G; Sauer R; Liersch T; Lancet Oncol; 2015 Aug; 16(8):979-89. PubMed ID: 26189067 [TBL] [Abstract][Full Text] [Related]
53. Bevacizumab biosimilar BEVZ92 versus reference bevacizumab in combination with FOLFOX or FOLFIRI as first-line treatment for metastatic colorectal cancer: a multicentre, open-label, randomised controlled trial. Romera A; Peredpaya S; Shparyk Y; Bondarenko I; Mendonça Bariani G; Abdalla KC; Roca E; Franke F; Melo Cruz F; Ramesh A; Ostwal V; Shah P; Rahuman SA; Paravisini A; Huerga C; Del Campo García A; Millán S Lancet Gastroenterol Hepatol; 2018 Dec; 3(12):845-855. PubMed ID: 30262136 [TBL] [Abstract][Full Text] [Related]
54. Randomised phase-II trial of CAPIRI (capecitabine, irinotecan) plus bevacizumab vs FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) plus bevacizumab as first-line treatment of patients with unresectable/metastatic colorectal cancer (mCRC). Souglakos J; Ziras N; Kakolyris S; Boukovinas I; Kentepozidis N; Makrantonakis P; Xynogalos S; Christophyllakis Ch; Kouroussis Ch; Vamvakas L; Georgoulias V; Polyzos A Br J Cancer; 2012 Jan; 106(3):453-9. PubMed ID: 22240792 [TBL] [Abstract][Full Text] [Related]
55. A retrospective study of bifractionated CPT-11 with LF5FU infusion (FOLFIRI-3) in colorectal cancer patients pretreated with oxaliplatin and CPT-11 containing chemotherapies. Viel E; Demarchi MF; Chaigneau L; Nguyen T; Legat C; Stein U; Thiery-Vuillemin A; Limat S; Pivot X; Borg C Am J Clin Oncol; 2008 Feb; 31(1):89-94. PubMed ID: 18376234 [TBL] [Abstract][Full Text] [Related]
56. Randomized multicenter phase II trial of bolus plus infusional fluorouracil/leucovorin compared with fluorouracil/leucovorin plus oxaliplatin as third-line treatment of patients with advanced colorectal cancer. Kemeny N; Garay CA; Gurtler J; Hochster H; Kennedy P; Benson A; Brandt DS; Polikoff J; Wertheim M; Shumaker G; Hallman D; Burger B; Gupta S J Clin Oncol; 2004 Dec; 22(23):4753-61. PubMed ID: 15570076 [TBL] [Abstract][Full Text] [Related]
57. Phase II study of combined chemotherapy with irinotecan and S-1 (IRIS) plus bevacizumab in patients with inoperable recurrent or advanced colorectal cancer. Komatsu Y; Yuki S; Sogabe S; Fukushima H; Nakatsumi H; Kobayashi Y; Iwanaga I; Nakamura M; Hatanaka K; Miyagishima T; Kudo M; Munakata M; Meguro T; Tateyama M; Sakata Y Acta Oncol; 2012 Sep; 51(7):867-72. PubMed ID: 22554343 [TBL] [Abstract][Full Text] [Related]
58. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. Fuchs CS; Marshall J; Mitchell E; Wierzbicki R; Ganju V; Jeffery M; Schulz J; Richards D; Soufi-Mahjoubi R; Wang B; Barrueco J J Clin Oncol; 2007 Oct; 25(30):4779-86. PubMed ID: 17947725 [TBL] [Abstract][Full Text] [Related]
59. A phase 2 randomised study of veliparib plus FOLFIRI±bevacizumab versus placebo plus FOLFIRI±bevacizumab in metastatic colorectal cancer. Gorbunova V; Beck JT; Hofheinz RD; Garcia-Alfonso P; Nechaeva M; Cubillo Gracian A; Mangel L; Elez Fernandez E; Deming DA; Ramanathan RK; Torres AH; Sullivan D; Luo Y; Berlin JD Br J Cancer; 2019 Jan; 120(2):183-189. PubMed ID: 30531832 [TBL] [Abstract][Full Text] [Related]